CDNA CareDx Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CDNA

Price (delayed)

$37.14

Market cap

$1.92B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.16

Enterprise value

$1.86B

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 98
Relative Valuation: Rel. Valuation: 13
Relative Profitability: Rel. Profitability: 32

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

Highlights
The debt has declined by 26% year-on-year and by 9% since the previous quarter
CDNA's gross profit is up by 21% year-on-year and by 11% since the previous quarter
CareDx's net income has plunged by 113% YoY but it has soared by 62% from the previous quarter
CareDx's EPS has plunged by 113% YoY but it has soared by 60% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.caredx.com
Peers: AGIO ARDX

Key stats

What are the main financial stats of CDNA

CDNA stock price

How has the CareDx stock price performed over time
Intraday
-1.25%
1 week
-6.52%
1 month
36.9%
1 year
189.25%
YTD
97.13%
QTD
30.32%

Financial performance

How have CareDx's revenue and profit performed over time
Revenue
$412.82M
Gross profit
$284.37M
Operating income
-$16.21M
Net income
-$8.19M
Gross margin
68.9%
Net margin
-2%
The operating income has dropped by 132% year-on-year but it rose by 47% since the previous quarter
CareDx's operating margin has plunged by 127% YoY but it has soared by 52% from the previous quarter
CareDx's net income has plunged by 113% YoY but it has soared by 62% from the previous quarter
The net margin has dropped by 111% year-on-year but it has surged by 64% since the previous quarter

Price vs fundamentals

How does CDNA's price correlate with its fundamentals

Growth

What is CareDx's growth rate over time

Valuation

What is CareDx stock price valuation
P/E
N/A
P/B
6.07
P/S
4.6
EV/EBIT
N/A
EV/EBITDA
414.36
EV/Sales
4.5
CareDx's EPS has plunged by 113% YoY but it has soared by 60% from the previous quarter
The stock's price to book (P/B) is 102% more than its 5-year quarterly average of 3.0 and 102% more than its last 4 quarters average of 3.0
The equity has decreased by 17% YoY but it has increased by 3.4% from the previous quarter
The price to sales (P/S) is 84% more than the last 4 quarters average of 2.5 and 28% more than the 5-year quarterly average of 3.6
The revenue has increased by 19% YoY and by 9% QoQ

Efficiency

How efficient is CareDx business performance
The ROIC has shrunk by 138% YoY but it rose by 42% QoQ
CareDx's ROS has plunged by 127% YoY but it has soared by 50% from the previous quarter
CDNA's return on assets has dropped by 115% year-on-year but it has surged by 60% since the previous quarter
The ROE has plunged by 114% YoY but it has soared by 60% from the previous quarter

Dividends

What is CDNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CDNA.

Financial health

How did CareDx financials performed over time
The company's quick ratio rose by 20% QoQ but it fell by 17% YoY
CDNA's current ratio is up by 19% since the previous quarter but it is down by 17% year-on-year
The debt is 94% smaller than the equity
The debt has declined by 26% year-on-year and by 9% since the previous quarter
The equity has decreased by 17% YoY but it has increased by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.